Atossa Therapeutics (ATOS) just unveiled an announcement.
Atossa Therapeutics, Inc. has expanded its board by appointing Dr. Tessa Cigler as a new Class II director, set to serve until the 2026 Annual Meeting of Stockholders. Dr. Cigler, a distinguished Harvard and Duke-educated physician with expertise in medical oncology and public health, will also join the Nominating and Governance Committee. Her extensive medical background includes leading clinical trials at Weill Cornell Breast Center, and she will receive standard non-employee director compensation. The company has also planned to provide her with a customary indemnification agreement.
For detailed information about ATOS stock, go to TipRanks’ Stock Analysis page.
